HK's Ascletis Pharma at near 2-year high on FDA's approval for drug application

Ascletis Pharma

18/01/2022 02:07

** Shares of biological products developer Ascletis Pharma
Inc  1672.HK  jump 15.3% to HK$6.17, their highest since
February 2020
    ** Stock on track for a seventh straight session of gains;
is fifth-biggest percentage gainer on the Hong Kong bourse, and
among the 30 most actively traded by turnover
    ** Co announces the Investigational New Drug application
approval by U.S. Food and Drug Administration (FDA) and
initiation of global development of ASC22 (Envafolimab), a
subcutaneously administered PD-L1 antibody for functional cure
of chronic hepatitis B  urn:newsml:reuters.com:*:nFWN2TV029
    ** Ascletis says it has obtained a global and exclusive
licence from Suzhou Alphamab Co Ltd to develop and commercialize
ASC22 for all viral diseases including Hepatitis B
    ** The Hang Seng Commerce & Industry Index  .HSNC  climbs
0.1% and healthcare index  .HSCIH  rises 0.3%
    ** The Hang Seng Composite Index  .HSCI  edges up 0.1%,
while the benchmark Hang Seng Index  .HSI  slips 0.1%
    

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))